The role of aminosalicylates in the treatment of ulcerative colitis

Acta Gastro-Enterologica Belgica

Volumn 65, Issue 4, 2002, Pages 196-199

  Van Assche, Gert ^a   Baert, Filip ^a   De Reuck, Marc ^a   De Vos, Martine ^a   De Wit, Olivier ^a   Hoang, Pierre ^a   Louis, Edouard ^a   Mana, Fazia ^a   Pelckmans, Paul ^a   Rutgeerts, Paul ^a   Van Gossum, Andre ^a   D'Haens, Geert ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Aminosalicylates; Mesalazine; Safety; Sulfasalazine; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; BECLOMETASONE DIPROPIONATE; BETAMETHASONE; BUDESONIDE; BUTYRIC ACID; CORTICOSTEROID; CYCLOSPORIN; ENEMA; HYDROCORTISONE; MESALAZINE; METHYLPREDNISOLONE; NICOTINE; SALAZOSULFAPYRIDINE; STEROID; TACROLIMUS;

BONE MARROW DEPRESSION; CANCER RISK; COLON RESECTION; COLORECTAL TUMOR; DESCENDING COLON; DIARRHEA; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LOCAL ANESTHESIA; MAINTENANCE THERAPY; NEPHROTOXICITY; PANCREATITIS; REVIEW; SIDE EFFECT; SUPPOSITORY; TREATMENT INDICATION; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; FEMALE; HUMANS; MALE; MESALAMINE; SULFASALAZINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 12244257494     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. SUTHERLAND L.R., MAY G.R., SHAFFER E.A. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann. Intern. Med., 1993, 118: 540-549.
2. MINER P., NOSTRANT T., WRUBLE L., HINES C., JOHNSON S., WILKINSON C., HOOP R. Multicenter trial of Pentasa for active ulcerative colitis. Gastroenterology, 1991, 100: A231.
3. RUTGEERTS P. Medical therapy of inflammatory bowel disease. Digestion, 1998, 59: 453-469.
4. JEWELL D.P., CAPRILLI R., MORTENSEN N., NICHOLLS R.J., WRIGHT J.P. Indication and timing of surgery for severe ulcerative colitis. Gastroenterol. International, 1991, 4: 161-164.
5. BROWN J., HAINES S., WILDING I.R. Colonic spread of three rectally administered mesalazine (Pentasa) dosage forms in healthy volunteers as assessed by gamma scintigraphy. Aliment Pharmacol. Ther., 1997, 11: 685-691.
6. SUTHERLAND L.R. Topical treatment of ulcerative colitis. Med. Clin. N. Am., 1990, 74: 119-131.
7. HANNAUER S.B. Dose-ranging study of mesalamine enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. Inflam. Bowel Dis., 1998, 4: 79-83.
8. MARSHALL J.K., IRVINE E.J. Rectal aminosalicylate therapy for distal ulcerative colitis. Aliment Pharmacol. Ther., 1995, 9: 293-300.
9. CAMPIERI M., GIONCHETTI P., BELLUZZI A., BRIGNOLA C., TAMPIERI M., IANNONE P., MIGLIOLI M., BARBARA L. Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active UC. Gut, 1991, 32: 929-931.
10. BIDDLE W.L., GREENBERGER N.J., SWAN J.T., MCPHEE M.S., MINER P.B. 5-aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis. Gastroenterology, 1988, 94: 1075-1079.
11. GIONCHETTI P., RIZZELLO F., VENTURI A., BRIGNOLA C., FERRETTI M., PERUZZO S., CAMPIERI M. Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis. Aliment Pharmacol. Therap., 1997, 11: 1053-1057.
12. MARTEAU P., NELET F., LE LU M., DEVAUX C. Adverse events in patients treated with 5-aminosalicylic acid: 1993-1994 pharmacovigilance report for Pentasa in France. Aliment Pharmacol. Ther., 1996, 10: 949-956.
13. ARDIZZONE S., PETRILLO M., IMBESI V., CERUTTI R., BOLLANI S., BIANCHI-PORRO G. Is maintenance therapy always necessary for patients with ulcerative colitis in remission? Aliment Pharmacol. Ther., 1999, 13: 373-379.
14. EADEN J., ABRAMS K., EKBOM A., JACKSON E., MAYBERR J. Colorectal cancer prevention in ulcerative colitis: a case control study. Aliment Pharmacol. Ther., 2000, 14: 145-153.